Summit Therapeutics Inc

(NASDAQ:SMMT)

Latest On Summit Therapeutics Inc (SMMT):

Date/Time Type Description Signal Details
2023-05-11 15:19 ESTNewsSummit Therapeutics GAAP EPS of -$1.43N/A
2023-05-11 15:19 ESTNewsSummit Therapeutics, Inc. (SMMT) Q1 2023 Earnings Call TranscriptN/A
2023-04-13 15:42 ESTNewsSummit Therapeutics: Another Billionaire Project That Isn't Going AnywhereN/A
2023-03-10 18:56 ESTNewsSummit Therapeutics Inc. (SMMT) Q4 2022 Earnings Call TranscriptN/A
2023-03-09 11:55 ESTNewsSummit Therapeutics GAAP EPS of -$0.07N/A
2023-02-03 17:22 ESTNewsSummit Therapeutics plunges as $500M rights offering expiresN/A
2023-01-27 17:52 ESTNewsSummit Therapeutics: Ivonescimab Deal Potential Mid-Term Growth DriverN/A
2023-01-20 14:20 ESTNewsSummit closes license deal for antibody therapy for cancer; $500M rights offering on trackN/A
2022-12-08 02:41 ESTNewsCTRM, NIU and GOTU among premarket losersN/A
2022-12-06 13:50 ESTNewsSummit Therapeutics spikes 38% on licensing deal for cancer candidateN/A
2022-11-09 18:55 ESTNewsSummit Therapeutics GAAP EPS of -$0.14, revenue of $0.22MN/A
2022-10-04 11:48 ESTNewsSummit Therapeutics slips on plans to terminate study for lead candidateN/A
2022-08-19 08:22 ESTNewsSummit Therapeutics spikes 47% after insider purchasesN/A
2022-08-17 12:44 ESTNewsSummit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its PortfolioN/A
2022-08-11 21:36 ESTNewsSummit Therapeutics GAAP EPS of -$0.17, revenue of $0.23MN/A
2022-07-27 01:30 ESTNewsSummit Therapeutics names Maky Zanganeh as co-CEO, presidentN/A
2022-07-14 17:00 ESTNewsSummit to explore additional trial for its bacteria-induced colon infection drugN/A
2022-06-23 07:11 ESTNewsSummit Therapeutics stock drops postmarket on $100M rights offeringN/A
2022-06-01 09:57 ESTNewsAnkur Dhingra is the new CFO of Summit TherapeuticsN/A
2022-05-11 17:28 ESTNewsSummit Therapeutics GAAP EPS of -$0.22, revenue of $0.25MN/A
2022-03-18 09:27 ESTNewsSummit Therapeutics GAAP EPS of -$0.28, revenue of $0.25MN/A
2021-12-24 02:57 ESTNewsSummit Therapeutics - Disappointing Data But Not An Outright FailureN/A
2021-12-20 20:47 ESTNewsSummit sheds more than a third after ridinilazole study misses primary endpointN/A
2021-10-08 21:20 ESTNewsSummit Therapeutics adds Kenneth Clark to board of directorsN/A
2021-09-22 18:21 ESTNewsSummit Therapeutics says FDA not in agreement with endpoint change for pivotal trialsN/A
2021-09-22 18:21 ESTNewsMRIN, ALPN, SMMT and LPTX among after hours moversN/A
2021-09-22 18:21 ESTNewsSummit Therapeutics plunges as unapproved change to trial endpoint surprises analystN/A
2021-07-22 16:46 ESTNewsSummit Therapeutics to join Russell 3000 IndexN/A
2021-07-22 16:45 ESTNewsSummit Therapeutics: A Full Investment Analysis Of This Antibiotic InnovatorN/A
2021-07-22 16:45 ESTNewsSummit Therapeutics presents data from Phase II ridinilazole study at ECCMID 2021N/A
2021-04-21 12:31 ESTNewsSummit Therapeutics commences rights offeringN/A
2021-03-26 21:50 ESTNewsSummit Therapeutics launches rights offeringN/A
2021-03-18 15:19 ESTEarnings EstimateAn EPS average of -$0.01 is estimated for the 2022 year.Buy
2021-03-18 15:19 ESTEarnings EstimateAn EPS average of -$0.01 is estimated for the 2021 year.Buy
2021-03-17 16:46 ESTNewsSummit Therapeutics reports Q4 resultsN/A
2021-02-26 17:48 ESTAnalyst RatingThe Analyst Target Price has increased from $4 to $4.5.Neutral
2020-12-04 19:09 ESTFinancialsCompany financials have been released.Neutral
2020-11-27 06:57 ESTFinancialsCompany financials have been released.Neutral
2020-11-27 00:34 ESTFinancialsCompany financials have been released.Neutral
2020-11-18 06:45 ESTFinancialsCompany financials have been released.Neutral
2020-11-18 04:49 ESTNewsSummit Therapeutics reports Q3 resultsN/A
2020-10-08 20:53 ESTFinancialsCompany financials have been released.Neutral
2020-10-07 07:45 ESTNewsSummit Therapeutics files for $200M mixed shelfN/A
2020-10-04 15:17 ESTFinancialsCompany financials have been released.Neutral
2020-10-01 03:54 ESTFinancialsCompany financials have been released.Neutral
2020-09-30 12:18 ESTEarnings EstimateAn EPS average of -$0.02 is estimated for the quarter ending on December 31, 2020.Buy
2020-09-29 19:48 ESTNewsSummit Therapeutics +3.8% as Zanganeh reports 7.8% stakeN/A
2020-09-29 19:48 ESTNewsSummit Therapeutics reports Q2 resultsN/A
2020-09-26 16:30 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 09:10 ESTFinancialsCompany financials have been released.Neutral

About Summit Therapeutics Inc (SMMT):

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridium difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. Summit Therapeutics Inc. was founded in 2003 and is based in Cambridge, Massachusetts.

SMMT Quotes by TradingView

See Advanced Chart

General

  • Name Summit Therapeutics Inc
  • Symbol SMMT
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 70
  • Fiscal Year EndJanuary
  • IPO Date2015-03-05
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.summitplc.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 496.65
  • Price/Book (Most Recent Quarter) 6.4
  • Enterprise Value Revenue 514.24
View More

Financials

  • Most Recent Quarter 2020-07-31
  • Operating Margin -6085%
  • Return on Assets -36%
  • Return on Equity -90%
  • Revenue 860000
  • Earnings Per Share $1.23
  • Revenue Per Share $0.01
  • Gross Profit 860000
  • Quarterly Earnings Growth 14.9%
View More

Highlights

  • Market Capitalization 483.06 million
  • PE Ratio -4.38
  • Analyst Target Price $4.5
  • Book Value Per Share $0.55
View More

Share Statistics

  • Shares Outstanding 82.58 million
  • Shares Float 21.64 million
  • % Held by Insiders 7357%
  • % Held by Institutions 10.54%
  • Shares Short 367244
  • Shares Short Prior Month 289991
  • Short Ratio 1.16
  • Short % of Float 1%
View More

Technicals

  • Beta 0.62
  • 52 Week High $10.99
  • 52 Week Low $1.94
  • 50 Day Moving Average 7.13
  • 200 Day Moving Average 4.98
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Summit Therapeutics Inc (SMMT) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Summit Therapeutics Inc (SMMT) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2021-01-312021-01-31-$0.90$0.00
2020-10-312020-11-16-$1.24-$0.01-12300%
2020-07-312020-09-29$N/A-$1.15-$0.02-5650%
2020-04-302020-06-02$N/A-$0.10
2019-10-312019-12-17$124000-$0.22-$0.4045%
2019-07-312019-10-11$126000-$0.20-$0.5664.29%
2019-04-302019-06-26$249000-$0.20-$0.16-25%
2019-01-312019-03-27$505000-$0.35-$0.24-45.83%
2018-10-312018-12-11$4.47 million-$0.65-$0.31-109.68%
2018-07-312018-09-20$52.65 million$2.12-$0.37672.97%
2018-04-302018-06-05$10.09 million-$0.52-$0.7530.67%
2018-01-312018-04-11$7.97 million-$1.15-$0.66-74.24%
2017-10-312017-12-06$3.35 million-$0.20-$0.5865.52%
2017-07-312017-08-31$25.05 million$1.10$0.35214.29%
2017-04-302017-06-14$2.24 million-$0.48-$0.17-182.47%
2017-01-312017-03-29$2.2 million-$0.50-$0.48-4.17%
2016-10-312016-12-15$695000-$0.45$3.01-114.95%
2016-07-312016-09-08$10000-$0.65-$0.650%
2016-04-302016-05-10$86000-$0.55-$0.8636.05%
2015-10-312015-12-17$490000-$0.59
2015-07-312015-08-27$519000-$0.52
2015-04-302015-05-06$625000-$0.11

Summit Therapeutics Inc (SMMT) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Summit Therapeutics Inc (SMMT) Chart:

Summit Therapeutics Inc (SMMT) News:

Below you will find a list of latest news for Summit Therapeutics Inc (SMMT) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Summit Therapeutics Inc (SMMT) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-1710CALL0 00TRUE00
2024-05-1720CALL0 0589.77TRUE00
2024-05-1730.97CALL1 96155.57TRUE0.310.47
2024-05-1740.55CALL72 300175FALSE0.382.24
2024-05-1750.75CALL319 589179.16FALSE0.6911.5
2024-05-1760.1CALL110 121155.4FALSE0.10
2024-05-1770CALL0 00FALSE00
2024-05-1780CALL0 00FALSE00
2024-05-1710PUT0 00FALSE00
2024-05-1720PUT0 00FALSE00
2024-05-1730.15PUT0 91153.68FALSE00
2024-05-1740.45PUT0 28159.49TRUE00
2024-05-1750PUT0 0233.74TRUE00
2024-05-1760PUT0 0277.4TRUE00
2024-05-1770PUT0 0486.58TRUE00
2024-05-1780PUT0 0438.49TRUE00
2024-06-2110CALL0 0382.17TRUE00
2024-06-2120CALL0 0305.19TRUE00
2024-06-2130.8CALL0 4338.63TRUE00
2024-06-2141.16CALL2545 0214.69FALSE1.160
2024-06-2150.35CALL1 1214.88FALSE0.350
2024-06-2160CALL0 0213.34FALSE00
2024-06-2170CALL0 0203.02FALSE00
2024-06-2110PUT0 00FALSE00
2024-06-2120PUT0 0232.34FALSE00
2024-06-2130.35PUT2 0215.66FALSE0.350
2024-06-2140PUT0 0223.86TRUE00
2024-06-2150PUT0 0222.01TRUE00
2024-06-2160PUT0 0212.91TRUE00
2024-06-2170PUT0 0198.82TRUE00
2024-07-1911.75CALL0 0258.19TRUE00
2024-07-1921.8CALL0 3276.04TRUE00
2024-07-1931.03CALL0 147368.16TRUE00
2024-07-1941.3CALL9 4574196.45FALSE0.50.63
2024-07-1950.9CALL118 827175.82FALSE0.350.64
2024-07-1960.55CALL10 1749153.49FALSE0.550
2024-07-1970.3CALL0 147191.41FALSE00
2024-07-1980.45CALL100 1260174.67FALSE0.450
2024-07-1910PUT0 00FALSE00
2024-07-1920PUT0 0164.25FALSE00
2024-07-1930.8PUT106 5216182.59FALSE0.80
2024-07-1941.55PUT1184 125200.28TRUE1.550
2024-07-1951.05PUT0 10205.18TRUE00
2024-07-1962.15PUT0 4190.93TRUE00
2024-07-1970PUT0 0187.78TRUE00
2024-07-1980PUT0 0197.92TRUE00
2024-10-1810CALL0 0215.26TRUE00
2024-10-1820CALL0 0233.87TRUE00
2024-10-1830CALL0 0243.15TRUE00
2024-10-1841.5CALL41 230156.8FALSE0.50.5
2024-10-1850.75CALL1 3106.6FALSE0.750
2024-10-1861CALL10 91149.44FALSE10
2024-10-1870.6CALL19 202124.81FALSE0.60
2024-10-1880CALL0 0141.25FALSE00
2024-10-1890.43CALL3 3127.83FALSE0.430
2024-10-1810PUT0 00FALSE00
2024-10-1820.25PUT0 1167.74FALSE00
2024-10-1830.66PUT0 10164.66FALSE00
2024-10-1841.15PUT0 5167.25TRUE00
2024-10-1852.55PUT0 1151.85TRUE00
2024-10-1860PUT0 0140.01TRUE00
2024-10-1870PUT0 0146.03TRUE00
2024-10-1880PUT0 0149TRUE00
2024-10-1890PUT0 0154.88TRUE00
2025-01-1712.5CALL0 770250.88TRUE00
2025-01-1722.05CALL0 608126.25TRUE00
2025-01-1731.9CALL14 221135.02TRUE0.40.27
2025-01-1741.55CALL5 271130.63FALSE1.550
2025-01-1751.08CALL21 1037111.55FALSE1.080
2025-01-1760CALL0 094.86FALSE00
2025-01-1770.8CALL9 64116.41FALSE0.80
2025-01-17100.3CALL0 1029109.11FALSE00
2025-01-1710.1PUT0 5400FALSE00
2025-01-1720.55PUT0 2145.57FALSE00
2025-01-1730.75PUT0 5138.67FALSE00
2025-01-1741.26PUT0 64131.76TRUE00
2025-01-1752.3PUT0 70126.41TRUE00
2025-01-1760PUT0 0135.15TRUE00
2025-01-1775.3PUT0 35122.6TRUE00
2025-01-17108PUT0 2130.42TRUE00

Latest SMMT Trades:

Date Shares Price
Jun 13, 2022 7:55 PM EST334$0.9325
Jun 13, 2022 7:55 PM EST100$0.9301
Jun 13, 2022 7:56 PM EST100$0.9301
Jun 13, 2022 7:57 PM EST100$0.9338
Jun 13, 2022 7:58 PM EST282$0.9354

Summit Therapeutics Inc (SMMT) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000159929820000024/0001599298-20-000024-index.htm
2019-06-14UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1599298/000000000019009889/0000000000-19-009889-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1599298/000089914019000232/0000899140-19-000232-index.htm
2020-09-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1599298/000089924320025702/0000899243-20-025702-index.htm
2020-09-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1599298/000089924320025705/0000899243-20-025705-index.htm
2020-09-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1599298/000089924320025706/0000899243-20-025706-index.htm
2020-09-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1599298/000089924320025707/0000899243-20-025707-index.htm
2020-09-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1599298/000089924320025711/0000899243-20-025711-index.htm
2020-09-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1599298/000089924320025712/0000899243-20-025712-index.htm
2020-09-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1599298/000089924320025713/0000899243-20-025713-index.htm
2020-09-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1599298/000089924320025714/0000899243-20-025714-index.htm
2019-01-11SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1599298/000091957419000328/0000919574-19-000328-index.htm
2020-03-26SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1599298/000091957420002580/0000919574-20-002580-index.htm
2020-05-15SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1599298/000091957420003557/0000919574-20-003557-index.htm
2020-06-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1599298/000091957420004158/0000919574-20-004158-index.htm
2019-01-22SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1599298/000092189519000132/0000921895-19-000132-index.htm
2019-12-10SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1599298/000092189519002958/0000921895-19-002958-index.htm
2019-12-27SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1599298/000092189519003085/0000921895-19-003085-index.htm
2020-01-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1599298/000092189520000126/0000921895-20-000126-index.htm
2020-01-23SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1599298/000092189520000159/0000921895-20-000159-index.htm
2020-09-28SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1599298/000092189520002482/0000921895-20-002482-index.htm
2020-09-28SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1599298/000092189520002483/0000921895-20-002483-index.htm
2020-10-07SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1599298/000092189520002546/0000921895-20-002546-index.htm
2020-10-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1599298/000092189520002547/0000921895-20-002547-index.htm
2020-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1599298/000092189520002557/0000921895-20-002557-index.htm
2020-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1599298/000092189520002819/0000921895-20-002819-index.htm
2019-01-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312519002553/0001193125-19-002553-index.htm
2019-01-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312519005734/0001193125-19-005734-index.htm
2019-01-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312519008984/0001193125-19-008984-index.htm
2019-02-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312519037930/0001193125-19-037930-index.htm
2019-04-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312519094502/0001193125-19-094502-index.htm
2019-05-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312519146672/0001193125-19-146672-index.htm
2019-06-12F-3Registration statement by foreign private issuershttps://www.sec.gov/Archives/edgar/data/1599298/000119312519170783/0001193125-19-170783-index.htm
2019-06-18CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1599298/000119312519175621/0001193125-19-175621-index.htm
2019-06-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312519175657/0001193125-19-175657-index.htm
2019-06-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312519176472/0001193125-19-176472-index.htm
2019-06-21424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1599298/000119312519178809/0001193125-19-178809-index.htm
2019-12-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312519307884/0001193125-19-307884-index.htm
2019-12-066-K/AReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312519308304/0001193125-19-308304-index.htm
2019-12-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312519322604/0001193125-19-322604-index.htm
2019-12-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312519323133/0001193125-19-323133-index.htm
2020-01-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312520013203/0001193125-20-013203-index.htm
2020-01-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312520015354/0001193125-20-015354-index.htm
2020-02-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312520026771/0001193125-20-026771-index.htm
2020-02-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312520050061/0001193125-20-050061-index.htm
2020-04-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312520107186/0001193125-20-107186-index.htm
2020-04-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312520112150/0001193125-20-112150-index.htm
2020-04-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312520127953/0001193125-20-127953-index.htm
2020-05-21S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1599298/000119312520148813/0001193125-20-148813-index.htm
2020-07-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312520199664/0001193125-20-199664-index.htm
2020-09-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000119312520247611/0001193125-20-247611-index.htm
2020-09-188-K12BNotification that a class of securities of successor issuer is deemed to be registered pursuant to section 12(b)https://www.sec.gov/Archives/edgar/data/1599298/000119312520248702/0001193125-20-248702-index.htm
2020-09-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1599298/000119312520257178/0001193125-20-257178-index.htm
2020-10-05S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendmentshttps://www.sec.gov/Archives/edgar/data/1599298/000119312520263921/0001193125-20-263921-index.htm
2020-10-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1599298/000119312520263928/0001193125-20-263928-index.htm
2020-10-05S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1599298/000119312520263935/0001193125-20-263935-index.htm
2020-10-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1599298/000119380520001233/0001193805-20-001233-index.htm
2020-10-073Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1599298/000119380520001258/0001193805-20-001258-index.htm
2020-09-1825-NSENotification filed by national security exchange to report the removal from listing and registration of matured, redeemed or rethttps://www.sec.gov/Archives/edgar/data/1599298/000135445720000486/0001354457-20-000486-index.htm
2019-01-18DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1599298/000159929819000002/0001599298-19-000002-index.htm
2019-03-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000159929819000005/0001599298-19-000005-index.htm
2019-03-2920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1599298/000159929819000008/0001599298-19-000008-index.htm
2019-06-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000159929819000011/0001599298-19-000011-index.htm
2019-10-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000159929819000017/0001599298-19-000017-index.htm
2019-10-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000159929819000018/0001599298-19-000018-index.htm
2019-12-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000159929819000024/0001599298-19-000024-index.htm
2020-01-02DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1599298/000159929820000001/0001599298-20-000001-index.htm
2020-04-3020-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1599298/000159929820000005/0001599298-20-000005-index.htm
2020-05-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000159929820000008/0001599298-20-000008-index.htm
2020-06-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000159929820000012/0001599298-20-000012-index.htm
2020-06-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000159929820000014/0001599298-20-000014-index.htm
2020-06-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000159929820000016/0001599298-20-000016-index.htm
2020-06-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000159929820000018/0001599298-20-000018-index.htm
2020-06-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000159929820000021/0001599298-20-000021-index.htm
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000159929820000024/0001599298-20-000024-index.htm
2020-07-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000159929820000026/0001599298-20-000026-index.htm
2020-07-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000159929820000028/0001599298-20-000028-index.htm
2020-07-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000159929820000031/0001599298-20-000031-index.htm
2020-08-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1599298/000159929820000033/0001599298-20-000033-index.htm
2020-09-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1599298/000159929820000039/0001599298-20-000039-index.htm
2019-06-20EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1599298/999999999519001397/9999999995-19-001397-index.htm
2020-10-15EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1599298/999999999520002867/9999999995-20-002867-index.htm
2019-04-26CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1599298/999999999719003399/9999999997-19-003399-index.htm